Familial Chylomicronemia Syndrome

Nov 28, 2025

Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA’s approval of REDEMPLO (plozasiran) on November 18, 2025—marking the company’s first FDA-approved medicine and the first-ever FDA-approved siRNA therapeutic for familial chylomicronemia syndrome (FCS) treatment. This historic approval r...

Jan 29, 2024

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide, encompassing conditions such as coronary artery disease and stroke. The growing occurrence of ASCVD, fueled by elevated risk factors, cardiovascular disease, and diabetes, is contributing to an expanding market f...

Mar 27, 2023

Triglycerides, the energy-providing lipids consumed from fat-containing food, have been known to cause severe health conditions in high levels, including acute pancreatitis. It is also associated with apolipoprotein C-III (APOCIII) and high probability of coronary artery disease (CAD). Triglyceride levels above a c...

Mar 21, 2023

AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque psoriasis signs and symptoms in a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 ...

Jul 24, 2020

A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS) affects 1 in 1 to 2 million people (Burnett and Hegele, 1999; Pouwels et al. 2008). As per DelveInsight, the total Familial chylomicronemia syndrome diagnosed prevalent population in the 7MM [the US, EU4 (Germany, Franc...